



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective May 1, 2022

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Lutathera*	lutetium Lu 177 dotatate	Oncology	A9513	1/1/2022
Cablivi	caplacizumab-yhdp	Blood Cell Deficiency	C9047	7/21/2019
Tepezza	teprotumumab	Ophthalmic Conditions	C9061 (eff 7/1/20), J3241 (eff 10/1/20)	3/1/2020
Vyepti	eptinezumab-jjmr	Miscellaneous Conditions	C9063 (eff 7/1/20), J3032 (eff 10/1/20)	5/1/2020
Viltepso	viltolarsen	Muscular Dystrophies	C9071 (eff 1/1/21), J1427 (eff 4/1/21)	11/15/2020
Cabeneuva	cabotegravir/rilpivirine extended-release injection	HIV	C9399, J3490	5/1/2021
Nulibry	fosdenopterin	Enzyme Deficiencies	C9399, J3490	6/1/2021
Evkeeza	evinacumab-dgnb	High Blood Cholesterol	C9399, J3490, J3590	5/1/2021
Amondys-45	casimersen	Muscular Dystrophies	C9399, J3490, J3590	5/1/2021
Saphnelo	anifrolumab	Inflammatory Conditions	C9399, J3490, J3590	10/1/2021
Nexvazyme	avalglucosidase alfa-ngpt	Enzyme Deficiencies	C9399, J3490, J3590	10/1/2021
Ryplazim	plasminogen, human-tvmh	Miscellaneous Conditions	C9399, J3490, J3590	3/1/2022
Vyvgart	efgartigimod alfa-fcab	Miscellaneous Conditions	C9399, J3490, J3590	3/1/2022
Apretude	cabotegravir	HIV	C9399, J3490, J3590	3/1/2022
Enjaymo	sutimlimab – jome	Miscellaneous Conditions	C9399, J3490, J3590	4/1/2022
Reblozyl	luspatercept-aamt	Blood Cell Deficiency	C9399, J3590, J0896 (eff 7/1/20)	1/1/2020
Eylea	aflibercept	Ophthalmic Conditions	J0178	5/1/2019
Beovu	brolucizumab-dbl	Ophthalmic Conditions	J0179	11/11/2019
Fabrazyme	agalsidase beta	Enzyme Deficiencies	J0180	7/21/2019
Lemtrada	alemtuzumab	Multiple Sclerosis	J0202	5/1/2019
Lumizyme	alglucosidase alfa	Enzyme Deficiencies	J0221	7/21/2019
Onpattro	patisiran	Amyloidosis	J0222	10/1/2019
Givlaari	givosiran	Miscellaneous Conditions	J0223 (eff 7/1/20)	1/1/2020
Prolastin-C	alpha1-proteinase inhibitor	Alpha 1 Deficiency	J0256	5/1/2019
Nulojix	belatacept	Transplant	J0485	5/1/2019
Brineura	cerliponase alfa	Enzyme Deficiencies	J0567	5/1/2019

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

± indicates the drug may be subject to site of care requirements

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective May 1, 2022

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Crysvita	burosumab-twza	Endocrine Disorders	J0584	10/1/2019
Botox	onabotulinumtoxinA	Neuromuscular Conditions	J0585	5/1/2019
Dysport	abobotulinumtoxinA	Neuromuscular Conditions	J0586	5/1/2019
Myobloc	rimabotulinumtoxinB	Neuromuscular Conditions	J0587	5/1/2019
Xeomin	incobotulinumtoxinA	Neuromuscular Conditions	J0588	5/1/2019
Ruconest	c1 esterase inhibitor	Hereditary Angioedema	J0596	5/1/2019
Berinerit	c1 esterase inhibitor	Hereditary Angioedema	J0597	5/1/2019
Depo-Testosterone	testosterone cypionate	Endocrine Disorders	J1060	2/1/2022
Cinryze	c1 esterase inhibitor	Hereditary Angioedema	J0598	5/1/2019
Ilaris	canakinumab	Inflammatory Conditions	J0638	5/1/2019
Xiaflex	collagenase clostridium histolyticum	Miscellaneous Conditions	J0775	5/1/2019
Adakveo	crizanlizumab-tmca	Miscellaneous Conditions	J0791 (eff 7/1/20)	1/1/2020
Cytogam	cytomegalovirus immune globulin	Immune Deficiency	J0850	3/1/2020
Aranesp*	darbepoetin alfa	Blood Cell Deficiency	J0881	5/1/2019
Epogen*	epoetin alfa	Blood Cell Deficiency	J0885	5/1/2019
Procrit*	epoetin alfa	Blood Cell Deficiency	J0885	5/1/2019
Mircera	methoxy peg-epoetin beta	Blood Cell Deficiency	J0888	5/1/2019
Prolia*	denosumab	Osteoporosis	J0897	5/1/2019
Soliris	eculizumab	Blood Modifying Agents	J1300	5/1/2019
Radicava	edaravone	Muscular Dystrophies	J1301	5/1/2019
Ultomiris	ravulizumab-cwvz	Blood Modifying Agents	J1303	5/1/2019
Vimizim	elosulfase alfa	Enzyme Deficiencies	J1322	7/21/2019
Epoprostenol	epoprostenol	Pulmonary Hypertension	J1325	5/1/2019
Flolan	epoprostenol	Pulmonary Hypertension	J1325	5/1/2019
Veletri	epoprostenol	Pulmonary Hypertension	J1325	5/1/2019
Exondys 51	eteplirsen	Muscular Dystrophies	J1428	5/1/2019
Monoferic	ferric derisomaltose	Anemia	J1437	3/1/2021

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

± indicates the drug may be subject to site of care requirements

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective May 1, 2022

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Injectafer	ferric carboxymaltose	Anemia	J1439	3/1/2021
Neupogen*	filgrastim	Blood Cell Deficiency	J1442	5/1/2019
Naglazyme	galsulfase	Enzyme Deficiencies	J1458	7/21/2019
Privigen	immune globulin	Immune Deficiency	J1459	5/1/2019
Asceniv	immune globulin	Immune Deficiency	J1554	7/21/2019
Cuvitru	immune globulin	Immune Deficiency	J1555	4/1/2022
Bivigam	immune globulin	Immune Deficiency	J1556	5/1/2019
Gammaplex	immune globulin	Immune Deficiency	J1557	5/1/2019
Xembify	immune globulin	Immune Deficiency	J1558	4/1/2022
Hizentra	immune globulin	Immune Deficiency	J1559	4/1/2022
Gammaked	immune globulin	Immune Deficiency	J1561	5/1/2019
Gamunex-C	immune globulin	Immune Deficiency	J1561	5/1/2019
Carimune NF	immune globulin	Immune Deficiency	J1566	5/1/2019
Gammagard SD	immune globulin	Immune Deficiency	J1566	5/1/2019
Octagam	immune globulin	Immune Deficiency	J1568	5/1/2019
Gammagard	immune globulin	Immune Deficiency	J1569	5/1/2019
Flebogamma Dif	immune globulin	Immune Deficiency	J1572	5/1/2019
Hyqvia	immune globulin	Immune Deficiency	J1575	4/1/2022
Panzyga	immune globulin	Immune Deficiency	J1599	5/1/2019
Simponi Aria	golimumab	Inflammatory Conditions	J1602	5/1/2019
Zulresso	brexanolone	Miscellaneous Conditions	J1632 (eff 10/1/20)	7/21/2019
Makena	hydroxyprogesterone caproate	Hormonal Supplementation	J1726	5/1/2019
Hydroxyprogesterone Caproate	hydroxyprogesterone caproate	Hormonal Supplementation	J1729	11/11/2019
Elaprase	idursulfase	Enzyme Deficiencies	J1743	7/21/2019
Remicade	infliximab	Inflammatory Conditions	J1745	5/1/2019
Somatuline Depot*	lanreotide	Endocrine Disorders	J1930	1/1/2022
Aldurazyme	laronidase	Enzyme Deficiencies	J1931	7/21/2019

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

± indicates the drug may be subject to site of care requirements

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective May 1, 2022

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Lupron Depot-Ped	leuprolide acetate	Endocrine Disorders	J1950	5/1/2019
Tysabri	natalizumab	Multiple Sclerosis	J2323	5/1/2019
Spinraza	nusinersen	Muscular Dystrophies	J2326	5/1/2019
Ocrevus [±]	ocrelizumab	Multiple Sclerosis	J2350	5/1/2019
Sandostatin LAR*	Octreotide	Endocrine Disorders	J2353	1/1/2022
Signifor LAR	pasireotide pamoate	Endocrine Disorders	J2502	1/1/2022
Macugen	pegaptanib sodium	Ophthalmic Conditions	J2503	5/1/2019
Adagen	pegademase bovine	Enzyme Deficiencies	J2504	5/1/2019
Krystexxa	pegloticase	Gout	J2507	5/1/2019
Lucentis	ranibizumab	Ophthalmic Conditions	J2778	5/1/2019
Cinqair	reslizumab	Asthma & Allergy	J2786	5/1/2019
Nplate	romiplostim	Blood Cell Deficiency	J2796	5/1/2019
Kanuma	sebelipase alfa	Enzyme Deficiencies	J2840	7/21/2019
Evenity	romosozumab	Osteoporosis	J3111	10/1/2019
Testosterone enanthate	testosterone enanthate	Endocrine Disorders	J3131	2/1/2022
Aveed	testosterone undecanoate	Endocrine Disorders	J3145	5/1/2019
Ilumya	tildrakizumab	Inflammatory Conditions	J3245	5/1/2020
Remodulin	treprostinil	Pulmonary Hypertension	J3285	5/1/2019
Treprostinil	treprostinil	Pulmonary Hypertension	J3285	7/21/2019
Triptodur	triptorelin	Endocrine Disorders	J3316	5/1/2019
Stelara IV	ustekinumab	Inflammatory Conditions	J3358	5/1/2019
Entyvio	vedolizumab	Inflammatory Conditions	J3380	5/1/2019
Mepsevii	vestronidase alfa-vjbk	Enzyme Deficiencies	J3397	7/21/2019
Luxturna	voretigene neparvovec-rzyl	Ophthalmic Conditions	J3398	5/1/2019
Xyosted	testosterone enanthate	Endocrine Disorders	J3490	2/1/2022
Fensolvi	leuprolide acetate	Endocrine Disorders	J3490	6/1/2020
Lupaneta Pack*	leuprolide acetate/norethindrone	Endocrine Disorders	J3490	5/1/2019

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

[±] indicates the drug may be subject to site of care requirements

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective May 1, 2022

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Oxlumo	lumasiran	Metabolic Disorders	J3490, C9074 (eff 4/1/21)	3/1/2021
Vyondys-53	golodirsén	Muscular Dystrophies	J3490, J1429 (eff 7/1/20)	3/1/2020
Scenesse	afamelanotide	Miscellaneous Conditions	J3490, J7352 (eff 1/1/21)	1/1/2020
Spravato	esketamine	Miscellaneous Conditions	J3490, S0013 (eff 1/1/21)	7/21/2019
Revcovi	elapegadomase-lvlr	Enzyme Deficiencies	J3590	5/1/2019
Leqvio	inclisiran	High Blood Cholesterol	J3590	3/1/2022
Vabysmo	faricimab-svoa	Ophthalmic Conditions	J3590	5/1/2022
Uplizna	inebilizumab-cdon	Miscellaneous Conditions	J3590, J1823 (eff 1/1/21)	7/15/2020
Zolgensma	onasemnogene abeparvovec-xioi	Muscular Dystrophies	J3590, J3399 (eff 7/1/20)	6/1/2019
Durolane	hyaluronate sodium	Osteoarthritis	J7318	5/1/2019
Genvisc 850	hyaluronate sodium	Osteoarthritis	J7320	5/1/2019
Hyalgan	hyaluronate sodium	Osteoarthritis	J7321	5/1/2019
Supartz	hyaluronate sodium	Osteoarthritis	J7321	5/1/2019
Supartz Fx	hyaluronate sodium	Osteoarthritis	J7321	5/1/2019
Visco-3	hyaluronate sodium	Osteoarthritis	J7321	5/1/2019
Hymovis	hyaluronate sodium	Osteoarthritis	J7322	5/1/2019
Euflexxa	hyaluronate sodium	Osteoarthritis	J7323	5/1/2019
Orthovisc	hyaluronate sodium	Osteoarthritis	J7324	5/1/2019
Synvisc	hyaluronate sodium	Osteoarthritis	J7325	5/1/2019
Synvisc-One	hyaluronate sodium	Osteoarthritis	J7325	5/1/2019
Gel-One	hyaluronate sodium	Osteoarthritis	J7326	5/1/2019
Monovisc	hyaluronate sodium	Osteoarthritis	J7327	5/1/2019
Gelsyn-3	hyaluronate sodium	Osteoarthritis	J7328	5/1/2019
Trivisc	hyaluronate sodium	Inflammatory Conditions	J7329	5/1/2019
Synjoynnt	sodium hyaluronate	Osteoarthritis	J7331	10/1/2019
Triluron	hyaluronate sodium	Osteoarthritis	J7332	10/1/2019
Durysta	bimatoprost	Ophthalmic Conditions	J7351 (eff 10/1/20)	5/1/2020

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

± indicates the drug may be subject to site of care requirements

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective May 1, 2022

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Atgam	lymphocyte immune globulin	Immune Deficiency	J7504	3/1/2020
Cutaquig	immune globulin	Immune Deficiency	J7799, J3590	4/1/2022
Zoladex*	goserelin acetate implant	Endocrine Disorders	J9202	5/1/2019
Gamifant	emapalumab-lzsg	Miscellaneous Conditions	J9210	5/1/2019
Lupron Depot*	leuprolide acetate	Endocrine Disorders	J9217	5/1/2019
Vantas*	Histrelin implant	Endocrine Disorders	J9225	5/1/2019
Supprelin LA*	Histrelin implant	Endocrine Disorders	J9226	5/1/2019
Rituxan*	rituximab	Inflammatory Conditions	J9312	5/1/2019
Ruxience*	rituximab-pvvr	Inflammatory Conditions	J9999, Q5119 (eff 7/1/20)	3/1/2020
Feraheme	ferumoxitol	Anemia	Q0138	3/1/2021
Zarxio*	filgrastim-sndz	Blood Cell Deficiency	Q5101	5/1/2019
Inflectra	infliximab-dyyb	Inflammatory Conditions	Q5103	5/1/2019
Renflexis	infliximab-abda	Inflammatory Conditions	Q5104	5/1/2019
Retacrit*	epoetin alfa-epbx	Blood Cell Deficiency	Q5106	5/1/2019
Nivestym*	filgrastim-aafi	Blood Cell Deficiency	Q5110	7/21/2019
Truxima*	rituximab-abbs	Inflammatory Conditions	Q5115	7/21/2019
Avsola	infliximab-axxq	Inflammatory Conditions	Q5121	7/15/2020
Riabni*	rituximab-arrx	Inflammatory Conditions	Q5123	3/1/2021
Testopel	testosterone implant	Endocrine Disorders	S0189	5/1/2019
Synagis	palivizumab	Respiratory Syncytial Virus	90378	5/1/2019

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

± indicates the drug may be subject to site of care requirements

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.